Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE1A | P54750 | 16/20 | 0.72 |
| ▸ | PDE1B | Q01064 | 16/20 | 0.72 |
| ▸ | PDE1C | Q14123 | 16/20 | 0.72 |
| ▸ | ESR1 | P03372 | 2/20 | 0.72 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.72 |
| ▸ | PSMB1 | P20618 | 3/20 | 0.62 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.62 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL285264 | 1.00 | PDE1A (0.72) | PDE1APDE1BPDE1CESR1ESR2 | |
| SCHEMBL285263 | 1.00 | PDE1A (0.72) | PDE1APDE1BPDE1CESR1ESR2 | |
| SCHEMBL7111397 | 0.87 | PDE1A (0.73) | PDE1APDE1BPDE1CESR1ESR2 | |
| SCHEMBL7148860 | 0.87 | PDE1A (0.73) | PDE1APDE1BPDE1CESR1ESR2 | |
| Idoxifene SCHEMBL19217 | 0.84 | PDE1A (1.00) | PDE1APDE1BPDE1CESR1ESR2 | |
| Idoxifene SCHEMBL3774574 | 0.84 | PDE1A (1.00) | PDE1APDE1BPDE1CESR1ESR2 | |
| Idoxifene SCHEMBL19216 | 0.84 | PDE1A (1.00) | PDE1APDE1BPDE1CESR1ESR2 | |
| SCHEMBL10349389 | 0.83 | PDE1A (0.73) | PDE1APDE1BPDE1CESR1ESR2 | |
| SCHEMBL18291033 | 0.83 | CYP19A1 (0.87) | PDE1APDE1BPDE1CESR1ESR2 | |
| SCHEMBL8767710 | 0.83 | PDE1A (0.76) | PDE1APDE1BPDE1CESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200030259-A1 | Antiestrogens and/or Aromatase Inhibitors for Use in Treating Obesity and Related Symptoms | REPROS THERAPEUTICS INC (US) | 2020-01-30 | — | — | US | disclosed |
| US-20150031656-A1 | COMBINATION THERAPY FOR TREATING ANDROGEN DEFICIENCY | REPROS THERAPEUTICS INC (US) | 2015-01-29 | — | — | US | disclosed |
| EP-2826475-A1 | Trans-clomiphene for treating diabetes in hypogonadal men | Repros Therapeutics Inc. (US) | 2015-01-21 | — | — | EP | disclosed |
| US-20130165524-A1 | TRANS-CLOMIPHENE FOR METABOLIC SYNDROME | REPROS THERAPEUTICS INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-8377991-B2 | Trans-clomiphene for metabolic syndrome | REPROS THERAPEUTICS INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-8372887-B2 | Trans-clomiphene for metabolic syndrome | REPROS THERAPEUTICS INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-20120022167-A1 | Trans-Clomiphene for Metabolic Syndrome | REPROS THERAPEUTICS INC. (US) | 2012-01-26 | — | — | US | disclosed |
| US-7935698-B2 | Heteroaryl-hydrazone compounds | SYNTA PHARMACEUTICALS CORPORATION (US) | 2011-05-03 | — | — | US | disclosed |
| US-7696202-B2 | IL-12 modulatory compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2010-04-13 | — | — | US | disclosed |
| US-20090099265-A1 | TRANS-CLOMIPHENE FOR METABOLIC SYNDROME | REPROS THERAPEUTICS INC. (US) | 2009-04-16 | — | — | US | disclosed |
| US-7338951-B2 | Pyridine compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2008-03-04 | — | — | US | disclosed |
| WO-2006124662-A1 | IL-12 MODULATORY COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2006-11-23 | — | — | WO | disclosed |
| US-20060223996-A1 | IL-12 modulatory compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2006-10-05 | — | — | US | disclosed |
| EP-1626725-A2 | HETEROCYCLIC COMPOUNDS FOR PREVENTING AND TREATING DISORDERS ASSOCIATED WITH EXCESSIVE BONE LOSS | Synta Pharmaceuticals Corporation (US) | 2006-02-22 | — | — | EP | disclosed |
| US-20050282809-A1 | Heteroaryl-hydrazone compounds | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2005-12-22 | — | — | US | disclosed |
| US-20050250774-A1 | Pyridine compounds | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2005-11-10 | — | — | US | disclosed |
| WO-2005000404-A2 | HETEROCYCLIC COMPOUNDS FOR PREVENTING AND TREATING DISORDERS ASSOCIATED WITH EXCESSIVE BONE LOSS | SYNTA PHARMACEUTICALS, CORP. (US) | 2005-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223996-A1 | IL-12 modulatory compounds | IL2, IL4, IFNG | PDE1A 2007/4885PDE1B 2137/4885PDE1C 1685/4885 |
| US-20050282809-A1 | Heteroaryl-hydrazone compounds | MMP12, IL1RN, CASP12 | PDE1A 1524/4885PDE1B 1968/4885PDE1C 2829/4885 |
| US-20050250774-A1 | Pyridine compounds | IL2, IL4, IL6 | PDE1A 3315/4885PDE1B 3350/4885PDE1C 3287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.